The BeSt story: On strategy trials in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 21, Issue 3, 2009, Pages 291-298

  Klarenbeek, Naomi B ^a   Allaart, Cornelia F ^a   Kerstens, Pit J S M ^b   Huizinga, Tom W J ^a   Dijkmans, Ben A C ^b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combination therapy; Result driven treatment; Rheumatoid arthritis; Tight control; Treatment strategy

Indexed keywords

ADALIMUMAB; ATLIZUMAB; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

AREA UNDER THE CURVE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; MOUTH ULCER; PATIENT CARE; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SULFASALAZINE;

EID: 67650129875     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832a2f1c     Document Type: Review

References (37)

1. Finckh A, Liang MH, Van Herckenrode CM, De Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a metaanalysis. Arthritis Rheum 2006;55:864-872.
2. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-451.
3. Haagsma CJ, Van Riel PL, De Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-1088.
4. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-134. This systematic review gives an overview of the effectiveness and toxicity of different DMARDS, alone and in combination.
5. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360-3370.
6. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-318.
7. Möttönen T, Hannonen P, Leirisalo-Repo M, et al., FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-1573.
8. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593.
9. St Clair EW, Van der Heijde DMFM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443.
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
11. Choy EH, Smith CM, Farewell V, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008;67:656-663.
12. Verstappen SM, Jacobs JW, Van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-1449.
13. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, doubleblind, parallel treatment trial. Lancet 2008;372:375-382. This large RCT in recent-onset RA patients showed the benefit of treatment with the combination MTX and etenercept compared with MTX alone.
14. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008;58:1310-1317. This RCT compared a step-up combination starting with SSZ with the initial combination of MTX, SSZ and HCQ while aiming at low disease activity.
15. Van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-1577.
16. Van Vollenhoven RF, Ernestam S, Geborek P, et al. In patients with early RA who fail initial MTX, the addition of anti-TNF yields better ACR and EULAR responses than the addition of conventional DMARDs: 1-years results of the SWEFOT trial [abstract #1003]. ACR Annual Scientific Meeting 2008;2008.
17. Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy versus its combination with adalimumab) in management of early active rheumatoid arthritis during the first year of evolution: data from the Guepard trial [abstract #1640]. ACR Annual Scientific Meeting 2008;2008.
18. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACo DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACo study [abstract #OP-0009]. EULAR Annual Scientific Meeting 2008;2008.
19. Van Eijk IC, Nielen MMJ, Van der Horst-Bruinsma IE, et al. Similar results of aggressive and conventional therapy in the first year of the STRategies in Early Arthritis Management (STREAM) study [abstract #1641]. ACR Annual Scientific Meeting 2008;2008.
20. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying antirheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008;67:815-822.
21. Van der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2008 doi: 10.1136/ARD.2008.092254. Four-year clinical and radiological results of the BeSt study.
22. Van der Heijde DMFM, Klareskog L, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-3939.
23. Rantalaiho V, Laasonen L, Kautiainen H, et al. Window of opportunity in early rheumatoid arthritis: combination therapy with FIN-RACo strategy during the first 2 years translates into less joint erosions in 11-years radiographs [abstract #2043]. ACR Annual Scientific Meeting 2008;2008.
24. Van Tuyl LHD, Voskuyl AE, Lems WF, et al. Rate of progression of the COBRA trial cohort after 11 years follow up [abstract #2000]. ACR Annual Scientific Meeting 2008;2008.
25. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-356.
26. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-3390.
27. Van der Kooij SM, De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 2008;61:4-12.
28. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. Clinical and radiological outcomes in recent onset rheumatoid arthritis after 5 years of DAS-steered treatment in the BeSt-study [abstract #1996]. ACR Annual Scientific Meeting 2008;2008.
29. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008;47:59-64.
30. Jones G, Lowenstein M, Calvo A, et al. The AMBITION study: superiority of tociluzumab vs. methotrexate monotherapy in patients with reumatoid arthritis [abstract #1210]. ACR Annual Scientific Meeting 2008;2008.
31. Van der Kooij SM, Le Cessie S, Goekoop-Ruiterman YPM, et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2008 doi: 10.1136/ARD.2008.093294. This subanalysis of the BeSt study showed that initial treatment with MTX and infliximab leads to better disease control than introducing the combination after failure on traditional DMARDs.
32. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-269.
33. Van der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2008;67:266-269.
34. Goekoop-RuitermanYPM, De Vries-Bouwstra JK, Kerstens PJSM, et al. DASdriven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2009 doi: 10.1136/ARD.2008.097683.
35. Van der Woude D, Visser K, Brand R, et al. Improved outcomes of drug-free remission with DAS-steered therapy compared to conventional therapy for rheumatoid arthritis [abstract #2046]. ACR Annual Scientific Meeting 2008;2008.
36. Kuper I, Hoekstra M, Ten Klooster P, et al. Remission can be achieved in 50% of early rheumatoid arthritis patients after 25 weeks in daily clinical practice [abstract #OP-0003]. EULAR Annual Congress 2008;2008.
37. Van Tuyl LH, Plass AM, Lems WF, et al. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007;66:974-976.